Table 3.
Relapse characteristics (n = 21)
| Characteristic | GIT 1992 | GIT 1996 | Total |
|---|---|---|---|
| Follow‐up patients with relapses, n (%) | 3 (14.3) | 18 (85.7) | 21 (15.7) |
| Total relapse events, n | 3 | 25 | 28 |
| 1 relapse | 3 | 12 | 15 |
| 2 relapses | 0 | 5 | 5 |
| 3 relapses | 0 | 1 | 1 |
| Sex, n | |||
| Female | 0 | 6 | 6 |
| Male | 3 | 12 | 15 |
| Age, years | 44, 65, 69 | 18, 30, 44, 49, 58, 60, 60, 60, 60, 61, 61, 63, 64, 64, 65, 65, 69, 69 |
Median, 61 Range, 18–69 |
| Ann Arbor Stage, n | |||
| I | 0 | 4 | 4 |
| II | |||
| II1 | 1 | 6 | 7 |
| II2 | 2 | 7 | 9 |
| IV | 0 | 1 | 1 |
| ECOG, n | |||
| 0 | 2 | 16 | 18 |
| 1 | 1 | 2 | 3 |
| 2 | 0 | 0 | 0 |
| Primary histology, n | |||
| Indolent | 1 | 8 | 9 |
| FL | 1 | 5 | 6 |
| MZL | 0 | 3 | 3 |
| Aggressive | 2 | 9 | 11 |
| T‐cell lymphoma | 0 | 1 | 1 |
| DLBCL | 2 | 8 | 10 |
| Indolent‐aggressive | 0 | 1 | 1 |
| Primary localization, n | |||
| Small bowel | 1 | 6 | 7 |
| Ileocecal region | 2 | 5 | 7 |
| Duodenum | 0 | 1 | 1 |
| Colon | 0 | 1 | 1 |
| Rectum | 0 | 1 | 1 |
| Ileocecal region + lung | 0 | 1 | 1 |
| Multilocular intestinal | 0 | 3 | 3 |
| Protocol‐deviation,a n | |||
| No | 2 | 7 | 9 |
| Yes | 0 | 0 | 0 |
| Protocol‐violation,b n | |||
| Yes | 1 | 11 | 12 |
| Chemotherapy | 0 | 8 | 8 |
| RT | 1 | 2 | 3 |
| RT + chemotherapy | 0 | 1 | 1 |
| First relapse histology, n | |||
| Indolent | 1 | 7 | 8 |
| Presumed indolent | 0 | 2 | 2 |
| Aggressive | 2 | 9 | 11 |
| Indolent‐aggressive | 0 | 0 | 0 |
| First relapse localization, n | |||
| Local | 1 | 3 | 4 |
| Distant | 2 | 14 | 16 |
| Local + distantc | 0 | 1 | 1 |
| First relapse interval,d months | 4, 5, 163 | 2, 4, 4, 5, 5, 6, 15, 16, 20, 24, 32, 46, 48, 61, 88, 97, 101, 172 |
Median, 20 Range, 2–172 |
| First relapse timing,e n | |||
| Early | 2 | 6 | 8 |
| Late | 1 | 12 | 13 |
| First salvage therapy, n | |||
| Surgery | 0 | 0 | 0 |
| Chemotherapy | 1 | 11 | 12 |
| Radiotherapy | 1 | 1 | 2 |
| Radiochemotherapy | 0 | 3 | 3 |
| Radiochemotherapy + surgery | 0 | 1 | 1 |
| Watch and wait | 1 | 2 | 3 |
| First salvage CR,f n | |||
| Persistent | 0 | 4 | 4 |
| Temporary | 0 | 6 | 6 |
| No | 3 | 8 | 11 |
| Re‐relapse interval,g months | 19, 27, 53, 75, 66, 170, 195 |
Median, 75 Range, 19–195 |
|
| Re‐salvage therapy, n | |||
| Chemotherapy | 3 | 3 | |
| Radiotherapy | 1 | 1 | |
| Radiochemotherapy | 1 | 1 | |
| Cytoreductive therapy | 1 | 1 | |
| No therapy | 1 | 1 | |
| Second salvage CR,h n | |||
| Persistent | 2 | 2 | |
| Temporary | 1 | 1 | |
| No | 4 | 4 | |
| Death, n | |||
| No | 1 | 7 | 8 |
| Yes | 2 | 11 | 13 |
| DOD, n | |||
| No | 0 | 0 | 0 |
| Yes | 2 | 11 | 13 |
Protocol deviation means dose deviation >5% and < 10%.
Protocol violation means dose deviation ≥10% or false radiation field size.
Local at first relapse and distant at second/third relapse.
Relapse interval between start of RT and first relapse.
Relapse timing is early within the first year after start of treatment and late after the first year after start of treatment.
First salvage CR means de novo complete remission after first salvage therapy.
Re‐relapse interval between start of RT and second or third relapse.
Second salvage CR means de novo complete remission after second or third salvage therapy.
Abbreviations: CR, complete response; DLBCL, diffuse large B‐cell lymphoma; DOD, died of disease; ECOG, Eastern Cooperative Oncology Group; FL, follicular lymphoma; MZL, marginal zone lymphoma; RT, radiation therapy.